蕁麻疹市場：上市済み薬剤およびパイプライン薬剤の評価、臨床試験、競合情勢

当レポートでは、蕁麻疹市場について調査し、疾患の概要、上市済み薬剤およびパイプライン薬剤の評価、臨床試験動向、競合情勢などを提供しています。

目次

第1章 序文

第2章 主な調査結果

第3章 疾患の情勢

• 疾患の概要
• 疫学の概要
• 治療の概要

第4章 上市済み薬剤の評価

第5章 価格設定と償還の評価

• メーカー価格
• 価格設定と償還までの時間

第6章 パイプライン薬剤の評価

第7章 臨床試験の評価

• 歴史的概要
• 相別概要
• ステータス別概要
• 進行中および計画中の試験の段階別概要
• 仮想コンポーネントによる臨床試験
• 地域別概要
• 単一国および多国籍試験、地域別
• 相別内訳の試験依頼者主要20社
• ステータス別内訳付き試験依頼者主要20社
• エンドポイントステータス別概要
• 人種・民族別概要
• 登録データ
• 臨床試験サイトの上位20か国
• 世界の主要20サイト
• 実現可能性分析- 地理的概要
• 実現可能性分析- ベンチマークモデル

第8章 取引情勢

第9章 商業的評価

• 主要な市場参入企業

第10章 将来の市場促進要因

第11章 付録

This reports provides a data-driven overview of the current and future competitive landscape in Urticaria therapeutics.

Synopsis

• In 2022, there will be more than 80 million diagnosed prevalent cases of urticaria across 16 pharmaceutical markets.
• Most of the leading marketed drugs for urticaria are second-generation H1-antihistamines, which are used as the first-line symptomatic treatment for the disease.
• Out of 50 drugs in urticaria pipeline, more than 20 molecules are currently in mid- to late-stage development.
• Among industry-sponsored trials, Novartis has sponsored the highest number of trials in urticaria over the past 10 years, followed by Genentech.
• Acquisitions accounted for over 35% of all deals in each of the regions except in South America and Africa, where licensing agreements are predominant.
• Within the next 30 months, regulatory filing for only one drug within urticaria space is expected.

Scope

GlobalData's Urticaria Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Retail or Manufacturer Price of Products
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Urticaria market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Urticaria market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents

1 Preface

• 1.1 Contents
• 1.2 Report Scope
• 1.3 List of Tables and Figures
• 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

• 3.1 Disease Overview
• 3.2 Epidemiology Overview
• 3.3 Treatment Overview

4 Marketed Drugs Assessment

• 4.1 Leading Marketed Drugs
• 4.2 Overview by Mechanism of Action
• 4.3 Overview by Route of Administration
• 4.4 Marketed Drugs Profiles and Sales Forecasts

5 Pricing and Reimbursement Assessment

• 5.1 Manufacturer Price
• 5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment

• 6.1 Phase III Pipeline Drugs
• 6.2 Overview by Development Stage
• 6.3 Overview by Molecule Type
• 6.4 Overview by Mechanism of Action
• 6.5 Overview by Route of Administration
• 6.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
• 6.7 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

• 7.1 Historical Overview
• 7.2 Overview by Phase
• 7.3 Overview by Status
• 7.4 Overview by Phase for Ongoing and Planned Trials
• 7.5 Trials with Virtual Components
• 7.6 Geographic Overview
• 7.7 Single-Country and Multinational Trials by Region
• 7.8 Top 20 Sponsors with Breakdown by Phase
• 7.9 Top 20 Sponsors with Breakdown by Status
• 7.10 Overview by Endpoint Status
• 7.11 Overview by Race and Ethnicity
• 7.12 Enrollment Data
• 7.13 Top 20 countries for Trial Sites
• 7.14 Top 20 Sites Globally
• 7.15 Feasibility Analysis - Geographic Overview
• 7.16 Feasibility Analysis - Benchmark Models

8 Deals Landscape

• 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
• 8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

• 9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

• 11.1 Methodology
• 11.2 Methodology - Sales Forecast
• 11.3 Methodology - Pricing and Reimbursement
• 11.4 Methodology - PTSR and LoA Analysis
• 11.5 About the Authors
• 11.6 Contact Us
• 11.7 Disclaimer